Uveal melanoma is the most common primary intraocular tumor in adults and often results not only in vision loss but also in metastatic death.
with poor prognosis include epithelioid cell type, extracellular matrix pattern, mitotic figures, heterogeneous nuclear and nucleolar size, and tumor infiltration by macrophages and/or lymphocytes. [6] [7] [8] Cytogenetic factors associated with poor prognosis include monosomy 3 and gain of chromosome 8q. [9] [10] [11] Molecular biologic factors associated with poor prognosis include class 2 gene expression profile 12 and overexpression or underexpression of specific genes. 13 Because most uveal melanomas are currently managed by eye-preserving methods such as plaque and proton beam radiotherapy that do not yield a pathologic specimen, a number of investigators are currently performing biopsy (usually fine needle aspiration biopsy [FNAB]) 14 of uveal melanomas prior to, or at the time of, ocular treatment to obtain representative tumor specimens for cytopathologic, cytogenetic, and/or molecular biologic analysis. Gene expression profiling of tumor cells seems to distinguish accurately between tumors having low metastatic potential (class 1 signature) from those who also have a short term low metastatic potential but slightly higher mid to long term risk (class 1B), and those having short term high metastatic potential (class 2 signature). 16 Gene expression profile assays use a RT-PCR to determine the expression of a panel of 15 genes, three of them controls, in the tumor sample.
This assay can be performed in fresh/frozen tumor aspirates or paraffin preserved tissue.
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The Melanoma Molecular Map Project
In recent years, many new discoveries about the cytogene tic and molecular biologic abnormalities in uveal melanoma cells, and the ways these features influence development and prognosis of metastatic tumors, have been published. 12, 16, 17 Because of the sheer volume of information available in multiple scientific journals, no single clinician or basic scientist can keep up with all of this information. This circumstance allows us to suppose we may already have the pieces of information necessary to solve the puzzle of metastatic uveal melanoma but have not done so because of the complexity of putting them together. 18 The Melanoma Molecular Map Project college website (www.mmmp.org) was launched recently as an ambitious non-profit initiative to enable the scientific community dedicated to melanoma research to gather and share the ever-growing published knowledge on melanoma in a systematic fashion and in a translational perspective. Hopefully, this initiative will lead us closer to solving our puzzle and in turn ultimately lead to improved patient survival.
Treatment of Metastatic Uveal Melanoma
Unfortunately, the impact of systemic therapy on the survival of patients with metastatic uveal melanoma is uncertain. Metastatic uveal melanoma has a dismal track record of responding to conventional intravenous chemotherapy. [16] [17] [18] [19] [20] 
